secwatch.observer — SEC 8-K summary
======================================

Issuer:     InMed Pharmaceuticals Inc. (INM)
CIK:        0001728328
Form:       8-K
Filed at:   2026-05-19T14:32:30+00:00
Accession:  0001213900-26-058795
Event type: m_and_a
Sentiment:  negative
Materiality: 1.00
Item codes: 1.01, 5.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

InMed to merge with Mentari; pre-Merger InMed holders to own ~1.51% of combined company
--------------------------------------------------------------------------------

- Merger: InMed shareholders to own ~1.51% of combined entity; Mentari stockholders ~98.49%.
- Concurrent $290M private placement led by Fairmount; funds operations through 2028.
- Mentari's lead programs: MT-001 (anti-PACAP) and MT-002 (anti-CGRP x PACAP bispecific) targeting migraine prevention.
- Pre-Merger InMed shareholders receive Contingent Value Rights (CVRs) for net proceeds from legacy asset sales.
- Closing conditions include $150M+ pre-closing financing, shareholder approvals, and Nasdaq listing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728328/000121390026058795/0001213900-26-058795-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728328/000121390026058795/ea0291482-8k425_inmed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-058795

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer